Enrofloxacin visual rapid detection method based on double functions of magnetic bead magnetic separation and signal output

Through the dual function of magnetic bead magnetic separation and signal output, the problems of low sensitivity and complex operation in the prior art are solved, and fast and sensitive enrofloxacin detection are achieved, which is suitable for field applications.

CN119044477AActive Publication Date: 2024-11-29ZHEJIANG DANSHUI FISHERY RESEARCH INSTITUTE (ZHEJIANG DANSHUI FISHERY ENVIRONMENTAL MONITORING STATION)

Patent Information

Application Number
CN202411166825.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-29
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

The existing enrofloxacin detection methods have problems such as low sensitivity, complex operation, needing precise instruments, and long-term consumption, and cannot achieve fast and on-site inspection.

Method used

Using a dual function of magnetic bead magnetic separation-signal output, enrofloxacin monoclonal antibody and bovine serum albumin are modified by carrier magnetic beads, combined with labeled magnetic beads, and the rapid and sensitive enrosal is achieved by using magnetic separation and absorbance detection. Star detection.

Benefits of technology

It realizes fast, sensitive and specific detection of enrofloxacin, simple operation, no precision instruments are required, and the detection limit reaches 0.18ng/mL, which is suitable for field applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119044477A_ABST
    Figure CN119044477A_ABST
Patent Text Reader

Abstract

The invention discloses a visual rapid detection method for enrofloxacin based on dual functions of magnetic bead magnetic separation and signal output. The method specifically comprises the following steps: 1) modifying an enrofloxacin monoclonal antibody on the surface of a carboxylated magnetic bead with the particle size of 100-1000nm, and closing to obtain an immunomagnetic bead dispersion liquid; (2) coupling the enrofloxacin-bovine serum albumin compound with carboxylated magnetic beads with the particle size of 10-50nm, and closing to obtain labeled magnetic bead dispersion liquid; 3) mixing the immunomagnetic bead dispersion liquid with a sample solution, and reacting to obtain a mixed dispersion liquid; 4) mixing the labeled magnetic bead dispersion liquid with the mixed dispersion liquid, performing magnetic separation after reaction, taking clear liquid, and detecting the absorbance of the clear liquid at 405nm; and 5) substituting the absorbance into the standard curve to obtain the enrofloxacin concentration. The method disclosed by the invention is simple, rapid and high in sensitivity, has visual qualitative / semi-quantitative capability, and can be used for rapidly detecting enrofloxacin on site.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of visualized detection, and in particular to a visualized rapid detection method for enrofloxacin based on the dual functions of magnetic bead magnetic separation and signal output. Background Art

[0002] Enrofloxacin (ENR), also known as ethyl ciprofloxacin, is a fluoroquinolone antibiotic that can achieve bactericidal effects by inhibiting the activity of DNA gyrase. It has the characteristics of a wide antibacterial range, high antibacterial activity, and strong tissue penetration, and is widely used in the treatment of diseases in aquatic products, livestock and poultry. However, the drug can cause potential toxic side effects to the human body, and large-scale use can induce bacterial resistance and endanger human health. The maximum limit of the total amount of enrofloxacin and ciprofloxacin in the muscle tissue of animal foods such as aquatic products is 100 μg / kg. Therefore, it is particularly important to achieve rapid and sensitive detection of enrofloxacin.

[0003] Traditional detection methods for enrofloxacin residues mainly include microbial inhibition method and instrumental analysis represented by liquid chromatography-mass spectrometry. Instrumental analysis has the advantages of high sensitivity and low detection limit, and is now the standard method for detecting enrofloxacin. However, its pretreatment is complicated and requires professional operation and expensive precision instruments, and it is impossible to achieve on-site detection; microbial inhibition method is time-consuming and unstable, and lacks timeliness. In recent years, rapid detection methods represented by enzyme-linked immunosorbent assay (ELISA) and lateral flow immunochromatography (LFIA) have developed rapidly. However, ELISA requires repeated washing during the detection process, and the operation is relatively cumbersome; LFIA is easy to operate, but it lacks in detection precision and accuracy. Summary of the invention

[0004] The purpose of the present invention is to explore a visual rapid detection method for enrofloxacin that integrates the dual functions of magnetic separation and signal output of magnetic beads (MBs) in view of the deficiencies of the prior art. The present invention provides a visual rapid detection method for enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads. The method of the present invention is sensitive, rapid, has good specificity, and is simple to operate. It can not only realize qualitative / semi-quantitative detection by visually observing color changes, but also realize quantitative detection by measuring absorption values, and can realize on-site rapid detection of enrofloxacin.

[0005] The technical solution adopted by the present invention is:

[0006] (I) A visual rapid detection method for enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads

[0007] The enrofloxacin visualization rapid detection method comprises the following steps:

[0008] 1) Activating the carrier magnetic beads to obtain activated carrier magnetic beads, then modifying the surface of the activated carrier magnetic beads with enrofloxacin monoclonal antibodies, and blocking with bovine serum albumin to obtain an immunomagnetic bead dispersion; the carrier magnetic beads are carboxylated magnetic beads with a particle size of 100 to 1000 nm; the mass ratio of the activated carrier magnetic beads to the enrofloxacin monoclonal antibodies is 1:0.02 to 0.1; the mass ratio of the activated carrier magnetic beads to the bovine serum albumin is 1:30 to 50; the phosphate buffer may also be added with a 0.01% Tween-20 solution and a 0.1% bovine serum albumin solution to reduce non-specific adsorption of non-target substances; the enrofloxacin monoclonal antibody is mouse-derived, IgG2b, protein G purified, with a purity greater than 95%, and a concentration of 1 mg / mL;

[0009] The step 1) comprises the following steps:

[0010] 1.1) Wash the carrier magnetic beads with MES buffer solution (2-(N-morpholine)ethanesulfonic acid), repeat the washing 1 to 3 times, disperse the washed carrier magnetic beads in an activation solution, and react at room temperature for 30 minutes to 1 hour to obtain an activated carrier magnetic bead dispersion;

[0011] 1.2) separating the activated carrier magnetic beads from the activated carrier magnetic bead dispersion by magnetic separation, washing the activated carrier magnetic beads with a borate buffer, repeating the washing 1 to 3 times, and dispersing the washed activated carrier magnetic beads in a borate buffer to obtain a borate dispersion of the activated carrier magnetic beads;

[0012] 1.3) mixing the borate dispersion of activated carrier magnetic beads with the enrofloxacin monoclonal antibody solution, and then reacting at room temperature for 1 to 4 hours to obtain a borate dispersion of antibody-carrier magnetic beads;

[0013] 1.4) adding a bovine serum albumin solution with a mass concentration of 1% to 5% to the borate dispersion of the antibody-carrier magnetic beads, reacting at room temperature for 1 to 4 hours to obtain a borate dispersion of the immunomagnetic beads; separating the immunomagnetic beads from the borate dispersion of the immunomagnetic beads by magnetic separation, washing the immunomagnetic beads with a phosphate (PBS) buffer, repeating the washing 1 to 3 times, and dispersing the washed immunomagnetic beads in a phosphate buffer to obtain an immunomagnetic bead dispersion.

[0014] 2) coupling enrofloxacin with bovine serum albumin to obtain an enrofloxacin-bovine serum albumin complex; activating the pre-labeled magnetic beads to obtain activated pre-labeled magnetic beads, then coupling the enrofloxacin-bovine serum albumin complex with the activated pre-labeled magnetic beads, and blocking with bovine serum albumin to obtain a labeled magnetic bead dispersion; the pre-labeled magnetic beads are carboxylated magnetic beads with a particle size of 10 to 50 nm;

[0015] In the step 2), the mass ratio between the activated pre-labeled magnetic beads and the enrofloxacin-bovine serum albumin complex is 4:3; the mass ratio between the activated pre-labeled magnetic beads and bovine serum albumin is 1:150-250.

[0016] According to the weight percentage, the step 2) comprises the following steps:

[0017] 2.1) Dissolve 2 parts of enrofloxacin, 1 part of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.25 parts of sodium salt of N-hydroxysuccinimide sulfonate in N,N-dimethylformamide, and react at room temperature for 8 to 16 hours to obtain solution A; dissolve 5 parts of bovine serum albumin in a phosphate buffer with a pH of 6 to 8 to obtain solution B; add solution A dropwise to solution B, stir and react at room temperature for 2 to 4 hours, dialyze and centrifuge, and then take the supernatant to obtain an enrofloxacin-bovine serum albumin complex solution;

[0018] The ratio between the mass of enrofloxacin and the volume of N,N-dimethylformamide is 10-30 mg: 0.5-1.5 mL; the ratio between the mass of bovine serum albumin and the volume of phosphate buffer is 30-70 mg: 2-4 mL; the volume ratio between solution A and solution B is 0.5-1.5: 2-4;

[0019] In step 2.1), the dialysis treatment process is: the mixture of liquid A and liquid B after stirring reaction is placed in a dialysis bag with a molecular weight cutoff of 8000-14000D, and dialyzed at 4°C for 3 days, with the dialysate being changed 3 times a day. In step 2.1), the centrifugal treatment conditions are: the centrifugal speed is 3000rpm or above, and the centrifugal time is 5-10min;

[0020] 2.2) Wash the pre-labeled magnetic beads with MES buffer solution (2-(N-morpholine)ethanesulfonic acid), repeat the washing 1 to 3 times, disperse the washed pre-labeled magnetic beads in an activation solution, and react at room temperature for 30 minutes to 1 hour to obtain an activated pre-labeled magnetic bead dispersion;

[0021] 2.3) separating the activated pre-labeled magnetic beads from the activated pre-labeled magnetic bead dispersion by magnetic separation, washing the activated pre-labeled magnetic beads with a borate buffer, repeating the washing for 1 to 3 times, and dispersing the washed activated pre-labeled magnetic beads in a borate buffer to obtain a borate dispersion of the activated pre-labeled magnetic beads;

[0022] 2.4) mixing the borate dispersion of activated pre-labeled magnetic beads with the enrofloxacin-bovine serum albumin complex solution, and reacting them at room temperature for 1 to 4 hours to obtain a borate dispersion of unblocked labeled magnetic beads;

[0023] 2.5) adding a bovine serum albumin solution with a mass concentration of 1% to 5% to the borate dispersion of unblocked labeled magnetic beads, reacting at room temperature for 1 to 4 hours to obtain a borate dispersion of labeled magnetic beads; separating the labeled magnetic beads from the borate dispersion of the labeled magnetic beads by magnetic separation, washing the labeled magnetic beads with phosphate (PBS) buffer, repeating the washing 1 to 3 times, and dispersing the washed labeled magnetic beads in phosphate buffer to obtain a labeled magnetic bead dispersion.

[0024] 3) mixing the immunomagnetic bead dispersion with the sample solution to be detected, and then rotating and mixing at room temperature for reaction. After the reaction is completed, the mixture is subjected to magnetic separation and washing, and then dispersed in a phosphate buffer solution (PBS) to obtain a mixed dispersion, wherein the components of the capture magnetic bead mixed dispersion include immunomagnetic beads with enrofloxacin captured on the surface and magnetic beads with no enrofloxacin captured on the surface; in the sample solution to be detected, the concentration range of enrofloxacin is 1 to 100 ng / mL, and the detection limit is 0.18 ng / mL;

[0025] The step 3) is specifically as follows: 40 parts by volume of an immunomagnetic bead dispersion having a concentration of 2 mg / mL (measured in terms of the concentration of magnetic nanoparticles) is mixed with 160 parts by volume of a sample solution to be tested; then the mixture is rotated and mixed at room temperature for at least ten minutes; after the reaction is completed, the mixture is subjected to magnetic separation and washing, and then dispersed in 178 parts by volume of a phosphate buffer solution (PBS) to obtain a mixed dispersion.

[0026] 4) Mixing the labeled magnetic bead dispersion with the mixed dispersion obtained in step 3), rotating and mixing at room temperature, and after the reaction, using a Thermo Fisher DynaMag TM -2 Magnetic separation is performed on a magnetic stand to obtain the clear liquid, and the absorbance value of the clear liquid at a specific wavelength is detected. The absorbance value of the clear liquid at a specific wavelength is the detection value of the sample solution to be detected; the specific wavelength is 405nm. In this process, the difference in magnetic separation speed when the immunomagnetic beads are combined with different numbers of labeled magnetic beads is specially used to detect enrofloxacin, in order to avoid the use of other signal markers and cumbersome washing processes, and simplify the detection process;

[0027] The step 4) is specifically as follows: 22 parts by volume of the labeled magnetic bead dispersion having a concentration of 0.4 mg / mL (in terms of the concentration of magnetic nanoparticles) are mixed with 178 parts by volume of the mixed dispersion; and the mixture is mixed and reacted at room temperature for at least ten minutes;

[0028] In step 4), after the reaction is completed, 1 to 2 enrichment treatments are performed, and then magnetic separation is performed to obtain a clear liquid; the process of the enrichment treatment is: after magnetic separation until the clear liquid is clear and free of impurities, the clear liquid is not discarded, and the precipitate is resuspended in the clear liquid by mixing. The purpose of the enrichment treatment (several magnetic separations and remixing) is to increase the difference in magnetic separation speed during detection and improve the detection sensitivity.

[0029] The mass ratio between the immunomagnetic beads contained in the immunomagnetic bead dispersion in step 3) and the labeled magnetic beads contained in the labeled magnetic bead dispersion in step 4) is 100:5-15. Within the above mass ratio range, the sensitivity of the detection method is the highest. In specific implementation, the mass ratio can be selected from the preferred range of the above mass ratio by screening competitive inhibition rate under different concentration conditions.

[0030] 5) Substituting the detected value into the pre-drawn standard curve, the concentration of enrofloxacin in the sample solution to be detected is obtained.

[0031] In the step 1) and the step 2), the pH of the activation solution is 6.0, and the activation solution is a MES buffer solution containing 10 mmol / L of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 15 mmol / L of N-hydroxysuccinimide sulfonic acid sodium salt (NHSS).

[0032] In the step 1) and the step 2), the pH of the MES buffer solution is 5-7; the pH of the borate buffer solution is 7-9; and the pH of the phosphate buffer solution is 6-8.

[0033] The process of establishing the pre-drawn standard curve is as follows: according to step 3) to step 4), enrofloxacin standard solutions of different concentrations are treated respectively to obtain the detection value corresponding to each enrofloxacin standard solution, and the concentration of the enrofloxacin standard solution and the corresponding detection value are linearly fitted to obtain the standard curve.

[0034] The present invention makes full use of the dual functions of magnetic separation and signal output of magnetic beads, competitively binds the labeled magnetic beads and the target enrofloxacin to the binding sites on the surface of the immunomagnetic beads, and innovatively utilizes the difference in magnetic separation speed when the immunomagnetic beads are combined with different numbers of labeled magnetic beads to detect enrofloxacin residues.

[0035] (II) A visual rapid detection kit for enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads

[0036] The kit includes an immunomagnetic bead dispersion and a labeled magnetic bead dispersion; in the immunomagnetic bead dispersion, the immunomagnetic beads are mainly formed by carrier magnetic beads that are surface-modified with enrofloxacin monoclonal antibodies and then blocked with bovine serum albumin; the labeled magnetic bead dispersion is mainly formed by pre-labeled magnetic beads coupled with enrofloxacin-bovine serum albumin complexes and then blocked with bovine serum albumin; the carrier magnetic beads use carboxylated magnetic beads with a particle size of 100 to 1000 nm; the pre-labeled magnetic beads use carboxylated magnetic beads with a particle size of 100 to 1000 nm. When used for detection, the mass ratio of the carrier magnetic beads to the labeled magnetic beads can be selected to be 70 to 150:8 to 15, preferably 100:5 to 15.

[0037] The method of the present invention mainly relates to immunomagnetic beads IMB modified with enrofloxacin monoclonal antibody 大 and bovine serum albumin-enrofloxacin (BSA-ENR) functionalized labeled magnetic beads MB 小 -BSA-ENR. Using the high separation efficiency and excellent optical properties of magnetic beads, a simple and stable nanobiosensor was constructed to achieve rapid, sensitive and specific detection of enrofloxacin.

[0038] The beneficial effects of the present invention are:

[0039] (1) The present invention uses magnetic beads with larger particle sizes as separation and enrichment tools to improve detection sensitivity, and also uses magnetic beads with smaller particle sizes as output signal tools to improve detection stability. 大 Combine different amounts of labeled magnetic beads MB 小 -BSA-ENR was used to detect enrofloxacin residues by using the difference in magnetic separation speed, and the test results were stable and accurate.

[0040] (2) The detection method of the present invention is simple and rapid, does not require sophisticated instruments, lowers the detection threshold, and can achieve on-site rapid detection of enrofloxacin residues, with a wide range of application scenarios.

[0041] (3) The detection kit of the present invention can realize qualitative or semi-quantitative detection only by observing the color change with the naked eye, without the need for precise instruments, and can achieve the goal of on-site quantitative or semi-quantitative rapid detection.

[0042] (4) The detection method of the present invention avoids the use of other signal markers and cumbersome washing processes, thus simplifying the detection process.

[0043] (5) The detection time of the detection method of the present invention is much shorter than that of the enzyme-linked immunosorbent assay and the colloidal gold immunofiltration method, and it also has a lower detection limit. The linear detection range can reach 1 to 100 ng / mL, and the detection limit can reach 0.18 ng / mL. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 Schematic diagram of the principle of the method of the present invention.

[0045] Figure 2 The standard curve is the absorbance value of large magnetic beads with different concentrations at a wavelength of 405nm.

[0046] Figure 3 The standard curve is the absorbance value of small magnetic beads with different concentrations at a wavelength of 405nm.

[0047] Figure 4 Schematic diagram of the absorbance value of the immunomagnetic beads at a wavelength of 450nm in the method of the present invention.

[0048] Figure 5 It is the ultraviolet absorption spectrum of the labeled magnetic beads in the method of the present invention.

[0049] Figure 6 It is the standard curve diagram of the method of the present invention in buffer.

[0050] Figure 7 This is the standard curve for implementing the method of the present invention in fish meat extract.

[0051] Figure 8 This is the standard curve for the implementation of the method of the present invention in pond water samples. DETAILED DESCRIPTION

[0052] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments, but the present invention is not limited thereto.

[0053] like Figure 1 As shown, the detection principle of the present invention is: enrofloxacin in the sample solution to be detected is firstly detected by immunomagnetic beads (IMB 大 ) captures and occupies the IMB 大 After magnetic separation and washing, labeled magnetic beads (MB 小 -BSA-ENR) and IMB 大 The remaining sites on the surface bind to the proteins; and finally, the quantitative detection of enrofloxacin is achieved by detecting the absorbance value of the supernatant after magnetic separation.

[0054] Among them, immunomagnetic beads IMB 大 Combine different amounts of labeled magnetic beads MB 小 -BSA-ENR magnetic separation speed is different. Immunomagnetic beads IMB 大 Binding labeled magnetic beads MB 小 -The more BSA-ENR there is, the faster the separation speed during magnetic separation.

[0055] The specific embodiments of the present invention are as follows:

[0056] In this embodiment, the carrier magnetic beads (carboxylated large magnetic beads) use carboxylated magnetic beads with a particle size of about 130 nm, and the pre-labeled magnetic beads (carboxylated small magnetic beads) use carboxylated magnetic beads with a particle size of about 20 nm. Figure 2 and Figure 3 As shown, the absorbance values ​​of the two magnetic beads at different concentrations at 405 nm obtained through preliminary experiments have a good linear relationship.

[0057] 1) Preparation of Enrofloxacin Monoclonal Antibody Modified IMB 大

[0058] 1.1) Prepare 400 μL of a mixed solution containing 10 mmol / L EDC and 15 mmol / L NHSS;

[0059] 1.2) Disperse 20 μL of 10 mg / mL carboxylated large magnetic beads (Shanghai Orun Micro-Nano New Materials Technology Co., Ltd., with a particle size of about 130 nm) in a 2-(N-morpholine)ethanesulfonic acid (MES) buffer at a pH of 6.0, perform magnetic separation and remove the washing supernatant in MES buffer in sequence and repeat 3 times, resuspend the treated product in 400 μL of the mixed solution of EDC and NHSS obtained in step 1.1), rotate and mix at room temperature for 30 minutes to obtain an activated carrier magnetic bead solution; perform magnetic separation and remove the washing supernatant in sequence in a borate buffer at a pH of 7.4 and repeat 3 times, and then disperse in 396 μL of borate buffer to obtain a borate buffer dispersion containing activated large magnetic beads;

[0060] 1.3) 396 μL of borate buffer dispersion containing 0.2 mg of activated carrier magnetic beads was mixed with 4 μL of a solution containing 0.004 mg of enrofloxacin monoclonal antibody (purchased from Wuhan Huamei Bioengineering Co., Ltd.), and the mixture was shaken at room temperature for 2.5 h to obtain enrofloxacin monoclonal antibody-modified IMB. 大 borate buffer dispersion;

[0061] 1.4) Add the enrofloxacin monoclonal antibody modified IMB to step 1.3) 大 400 μL of a 2% bovine serum albumin solution was added to the borate buffer dispersion, and the mixture was shaken at room temperature for 1 h. The steps of magnetic separation and removal of the washing supernatant were repeated 3 times with a phosphate buffer at pH 7.4, and then dispersed in 100 μL of phosphate buffer to obtain an IMB containing bovine serum albumin blocked and enrofloxacin monoclonal antibody modified. 大 Phosphate dispersion (IMB 大 The final concentration was 2 mg / mL) and stored at 4°C until use.

[0062] Figure 4 Schematic diagram of the absorbance value of the immunomagnetic beads at a wavelength of 450nm in the method of the present invention. 大 -COOH), large magnetic beads-bovine serum albumin complex (MB 大 -BSA) and immunomagnetic beads (IMB 大 ) is the absorbance value after binding to enzyme-labeled secondary antibody.

[0063] As can be seen from the figure, MB 大 -COOH and MB 大 -OD of BSA 450 There is only a slight difference in the value. 大 OD 450 The value is much higher than the other two, which is due to the enzyme-labeled secondary antibody and IMN 大 The surface antibodies reacted immune-mediated, catalyzing 3,3',5,5'-tetramethylbenzidine (TMB) to form oxidation products, which produced strong absorbance at 450nm. 大 Preparation was successful.

[0064] 2) MB 小 Preparation of -BSA-ENR

[0065] 2.1) Dissolve 20 mg of enrofloxacin, 10 mg of NHSS and 12.5 mg of EDC in 1 mL of N,N-dimethylformamide (DMF) and shake at room temperature overnight to prepare solution A; dissolve bovine serum albumin (2.5 mg of bovine serum albumin per mg of enrofloxacin) in phosphate buffer at pH 7.4 to prepare solution B; add 1 mL of solution A dropwise into 3 mL of solution B while stirring, and then stir at room temperature for 3 h, then put the mixture into a dialysis bag (8000-14000D), dialyze at 4°C for 3 days, change the dialysate 3 times a day, centrifuge (3000 rpm, 5 min), take the supernatant, and obtain a dispersion containing BSA-ENR complex, which is diluted 10 times before use (the use concentration is 0.6 mg / mL, based on the concentration of bovine serum albumin).

[0066] 2.2) Prepare 400 μL of a mixed solution of 10 mmol / L EDC and 15 mmol / L NHSS; disperse 20 μL of 2 mg / mL carboxylated small magnetic beads (Xi'an Ruixi Biotechnology Co., Ltd., with a particle size of about 20 nm) in a 2-(N-morpholine)ethanesulfonic acid (MES) buffer at a pH of 6.0, perform magnetic separation and remove the washing supernatant in MES buffer in sequence and repeat the steps three times, resuspend in 400 μL of a mixed solution of EDC and NHSS, rotate and mix at room temperature for 30 minutes to obtain an activated carrier magnetic bead solution; perform magnetic separation and remove the washing supernatant in sequence and repeat the steps three times with a borate buffer at a pH of 7.4 on the activated carrier magnetic bead solution, and then disperse in 350 μL of a borate buffer to obtain a borate dispersion of activated pre-labeled magnetic beads;

[0067] 2.3) Mix 350 μL of the borate dispersion of activated pre-labeled magnetic beads with 50 μL of a dispersion containing 0.03 mg of BSA-ENR complex (0.75 mg BSA-ENR complex per mg MB). 小 ) and shaken at room temperature for 2.5 h to obtain MB 小 - Borate buffer dispersion of BSA-ENR;

[0068] 2.4) Repeat step 3.3) with MB 小 400 μL of 2% bovine serum albumin solution was added to the borate buffer dispersion of BSA-ENR, and the mixture was shaken at room temperature for 1 h. The steps of magnetic separation and waste liquid removal were repeated 3 times with phosphate buffer at pH 7.4, and then the mixture was dispersed in 100 μL phosphate buffer to obtain MB containing BSA. 小 -BSA-ENR phosphate buffered saline dispersion (MB 小 The final concentration of -BSA-ENR was 0.4 mg / mL, based on the concentration of small magnetic beads), and stored at 4°C until use.

[0069] Figure 5 The bovine serum albumin-enrofloxacin complex (BSA-ENR), carboxylated small magnetic beads (MB 小 -COOH), small magnetic beads-bovine serum albumin-enrofloxacin complex (MB 小 -BSA-ENR) UV-vis absorption spectrum. As can be seen from the figure, BSA-ENR has a protein characteristic absorption peak at 278nm, MB 小 -BSA-ENR also showed a characteristic peak at 278nm, while MB 小 There is no such peak in the determination results of -COOH, so it can be explained that MB 小 -Successful preparation of BSA-ENR complex.

[0070] 3) Detection of enrofloxacin in buffer

[0071] 3.1) Establishing the relationship between enrofloxacin concentration and OD 405 Standard curve model between;

[0072] 3.1.1) Prepare a series of solutions with known concentrations (10 -2 ~10 4 ng / mL) of enrofloxacin solution.

[0073] 3.1.2) Add 40 μL of IMB blocked with 0.08 mg of bovine serum albumin obtained in step 1.4) 大 Phosphate dispersion (concentration of 2 mg / mL) and 160 μL of different enrofloxacin concentrations (10 -2 ~10 4 ng / mL) solution, placed on a rotary mixer for reaction at room temperature for 10 min, the reaction mixture was subjected to sequential magnetic separation and removal of the washing supernatant using a phosphate buffer solution with a pH of 6.0 and repeated 3 times, and then dispersed in 178 μL of phosphate buffer solution to obtain immunomagnetic nanoparticles (IMB) with surface modified enrofloxacin. 大 -ENR) and unmodified enrofloxacin magnetic nanoparticles (IMB 大 -Non ENR) composed of a mixed solution;

[0074] 3.1.3) Take the mixture obtained in step 3.1.2) and add 22 μL of 0.4 mg / mL bovine serum albumin-blocked MB 小 -BSA-ENR phosphate buffer dispersion was placed on a rotary mixer for reaction at room temperature for 10 min, magnetic separation was performed and resuspended (without removing the supernatant), and the supernatant was immediately removed after magnetic separation at room temperature for 10 s to measure the OD 405 value.

[0075] 3.1.4) The OD obtained in step 3.1.3) above 405 The standard curve was established by fitting the values ​​with the known concentrations of enrofloxacin in the samples.

[0076] In this example, the test results of 11 known different enrofloxacin concentrations and sub-examples are shown in the following table. The test parameters and performances of the present invention applied to the 10 concentration examples are shown in the following table:

[0077]

[0078] A relationship curve was established with the logarithmic value of the enrofloxacin concentration as the abscissa and the absorbance value at 405 nm as the ordinate. It can be seen that the linear detection range of this embodiment is 1 to 100 ng / mL, and the linear regression equation is: y=0.3822logx+1.0808(r 2 =0.992), the detection limit is 0.18 ng / mL (such as Figure 6 (A) and Figure 6 (B)).

[0079] Depend on Figure 6 As can be seen from (B), as the concentration of enrofloxacin increases, the color depth of the clear solution increases. Therefore, the method of the present invention can be used for visual detection of the concentration of enrofloxacin.

[0080] 4) Detection of Enrofloxacin in Fish Tissue Extracts

[0081] 4.1) Fish sample pretreatment

[0082] 4.1.1) Weigh 3 g of chopped sample into a centrifuge tube;

[0083] 4.1.2) Add 6 g of anhydrous sodium sulfate and 18 mL of acetonitrile-1% FA (formic acid) solution twice to the mixture in step 4.1.1), and vortex for 10 minutes to obtain a mixed solution containing aqueous product tissue;

[0084] 4.1.3) Centrifuging the mixed solution of the aqueous product tissue obtained in step 4.1.2) at 8000 rpm for 8 min at room temperature to obtain a supernatant;

[0085] 4.1.4) Take 6 mL of the supernatant obtained in step 4.1.3) above, blow dry with nitrogen at 50°C, add 1 mL of phosphate buffer with a pH of 6.0 to dissolve, vortex for 2 min, filter with a microporous filter membrane with a pore size of 0.22 μm to obtain an extract of aquatic product tissue, and store at 4°C for later use;

[0086] 4.2) Establish the relationship between enrofloxacin concentration in fish tissue extract and OD 405 The standard curve between

[0087] 4.2.1) Prepare a series of known concentrations (10 -2 ~10 4 ng / mL) of enrofloxacin solution.

[0088] 4.2.2) Add 40 μL of IMB blocked with 0.08 mg of bovine serum albumin obtained in step 1.4) 大 Phosphate dispersions were mixed with 160 μL of different enrofloxacin concentrations (10 -2 ~10 4ng / mL) of fish tissue extract, placed on a rotary mixer for reaction at room temperature for 10 min, the reaction mixture was subjected to sequential magnetic separation and removal of the washing supernatant using a phosphate buffer solution with a pH of 6.0 and repeated 3 times, and then dispersed in 178 μL of phosphate buffer solution to obtain immunomagnetic nanoparticles (IMB) with surface modified enrofloxacin. 大 -ENR) and unmodified enrofloxacin magnetic nanoparticles (IMB 大 -Non ENR) composed of a mixed solution;

[0089] 4.2.3) Take the mixture obtained in step 4.2.2) and add 22 μL of MB blocked with bovine serum albumin. 小 -BSA-ENR phosphate buffer dispersion was placed on a rotary mixer for reaction at room temperature for 10 min, magnetic separation was performed and resuspended (without removing the supernatant), and the supernatant was immediately removed after magnetic separation at room temperature for 10 s to measure the OD 405 value.

[0090] 4.2.4) The OD obtained in step 4.2.3) above 405 The standard curve was established by fitting the values ​​with the known concentration of enrofloxacin in the samples; the obtained standard curve is shown in Figure 7 ;

[0091] 4.3) The aquatic product samples to be tested are treated according to step 4.1) to obtain aquatic product extracts, and enrofloxacin solutions of known concentrations are added to the aquatic product extracts (the final enrofloxacin concentrations in the aquatic product extracts are: 4 ng / mL, 40 ng / mL and 80 ng / mL), and then treated according to steps 4.2.1) to 4.2.4) to obtain absorbance values, which are compared with the standard curve model obtained in step 4.2) ( Figure 7 ) to obtain the concentration of enrofloxacin in the aquatic product sample to be tested. The test results and accuracy are shown in the following table:

[0092]

[0093] The average recovery rate of the method of the present invention in the detection of fish samples is between 81.9% and 94.7% (the average recovery rate is 100% which is the most accurate, and those skilled in the art believe that the recovery rate is between 80% and 120% which is good). This shows that the nano biosensor based on the dual functions of magnetic separation and signal output of magnetic nanoparticles of the present invention can be well applied to the detection of enrofloxacin in aquatic product samples.

[0094] 5) Detection of Enrofloxacin in Pond Water Samples

[0095] 5.1) Pretreatment of pond water samples

[0096] 5.1.1) The pond water sample was allowed to settle for 48 hours, filtered through a microporous filter membrane with a pore size of 0.22 μm, and then 10% volume of 100 mmol / L phosphate buffer was added to obtain an extract of the pond water sample, which was stored at 4°C for later use.

[0097] 5.2) Establish the relationship between enrofloxacin concentration and OD in pond water sample extract 405 The standard curve between

[0098] 5.2.1) Prepare a series of known concentrations (10 -2 ~10 4 ng / mL) of enrofloxacin solution;

[0099] 5.2.2) Prepare a standard curve according to steps 4.2.2) to 4.2.4). The obtained standard curve model is shown in Figure 8 .

[0100] 5.3) Treat the pond water sample to be tested according to step 5.1) to obtain a pond water sample extract, add enrofloxacin solution of known concentration to the pond water sample extract (the final enrofloxacin concentrations in the pond water sample extract are: 4ng / mL, 40ng / mL and 80ng / mL), and then treat it according to steps 4.2.1) to 4.2.4) to obtain the absorbance value, and compare it with the standard curve model obtained in step 5.2) ( Figure 8 ) to obtain the enrofloxacin concentration in the pond water sample extract to be tested, as shown in the following table:

[0101]

[0102] The average recovery rate of the method of the present invention in the detection of fish samples is between 85.9% and 95.7% (the average recovery rate is 100% which is the most accurate, and those skilled in the art believe that the recovery rate is between 80% and 120% which is good). This shows that the nano biosensor based on the dual functions of magnetic separation and signal output of magnetic nanoparticles of the present invention can be well applied to the detection of enrofloxacin in pond water samples.

[0103] 6) Compared with the existing rapid detection method of enrofloxacin, the results are as follows:

[0104]

[0105] The detection time of this method is much shorter than that of enzyme-linked immunosorbent assay and colloidal gold immunofiltration method, and the detection limit is much lower than that of Raman spectroscopy.

[0106] It can be seen from the above embodiments that the present invention proposes a visual rapid detection method for enrofloxacin based on the dual functions of magnetic bead magnetic separation and signal output, which is sensitive, rapid, simple to operate, does not require complex and precise instruments, has the potential for on-site rapid detection of enrofloxacin, and is expected to become a means of on-site rapid detection with good development prospects.

[0107] The above specific implementations are used to explain the present invention, rather than to limit the present invention. Any modifications and changes made to the present invention within the spirit of the present invention and the protection scope of the claims shall fall within the protection scope of the present invention. The above description is only a preferred implementation of the present invention, so any equivalent changes or modifications made according to the structure, features and principles described in the scope of the patent application of the present invention are included in the scope of the patent application of the present invention.

Claims

1. A visual rapid detection method for enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads, characterized in that: The following steps are involved: 1) activating the carrier magnetic beads to obtain activated carrier magnetic beads, then modifying the surface of the activated carrier magnetic beads with enrofloxacin monoclonal antibodies, and obtaining an immunomagnetic bead dispersion after blocking; The carrier magnetic beads are carboxylated magnetic beads with a particle size of 100 to 1000 nm; 2) activating the pre-labeled magnetic beads to obtain activated pre-labeled magnetic beads, and then coupling the enrofloxacin-bovine serum albumin complex with the activated pre-labeled magnetic beads, and obtaining a labeled magnetic bead dispersion after blocking; The pre-labeled magnetic beads are carboxylated magnetic beads with a particle size of 10 to 50 nm; 3) mixing the immunomagnetic bead dispersion with the sample solution to be detected, rotating and mixing at room temperature for reaction, and after the reaction is completed, performing magnetic separation and washing, and then dispersing in a phosphate buffer to obtain a mixed dispersion; 4) After mixing the labeled magnetic bead dispersion and the mixed dispersion, the mixture is rotated and mixed at room temperature for reaction. After the reaction is completed, the clear liquid is obtained by magnetic separation, and the absorbance value of the clear liquid at a specific wavelength is detected. The absorbance value of the clear liquid at the specific wavelength is the detection value; 5) Substituting the detected value into the pre-drawn standard curve, the concentration of enrofloxacin in the sample solution to be detected is obtained.

2. The visual rapid detection method for enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: In the step 4), after the reaction is completed, one to two enrichment treatments are performed, and then magnetic separation is performed to obtain a clear liquid; the process of the enrichment treatment is: after magnetic separation, the precipitate is resuspended in the clear liquid.

3. The visual rapid detection method for enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: In the step 1), the mass ratio of the activated carrier magnetic beads to the enrofloxacin monoclonal antibody is 1:0.02-0.1; in the step 2), the mass ratio of the activated pre-labeled magnetic beads to the enrofloxacin-bovine serum albumin complex is 4:

3.

4. The method for rapid visualization detection of enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: The mass ratio between the immunomagnetic beads in step 3) and the labeled magnetic beads in step 4) is 100:5-15.

5. The visual rapid detection method for enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: In the step 4), the specific wavelength is 405 nm.

6. The method for rapid visualization detection of enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: In the sample solution to be detected, the concentration of enrofloxacin is 1-100 ng / mL, and the detection limit is 0.18 ng / mL.

7. The method for rapid visualization detection of enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: The step 1) comprises the following steps: 1.1) washing the carrier magnetic beads with MES buffer solution, dispersing the washed carrier magnetic beads in an activation solution, and reacting at room temperature to obtain an activated carrier magnetic bead dispersion; 1.2) separating the activated carrier magnetic beads from the activated carrier magnetic bead dispersion by magnetic separation, washing the activated carrier magnetic beads with a borate buffer, and dispersing the washed activated carrier magnetic beads in a borate buffer to obtain a borate dispersion of the activated carrier magnetic beads; 1.3) mixing the borate dispersion of activated carrier magnetic beads with the enrofloxacin monoclonal antibody solution, and then reacting at room temperature for 1 to 4 hours to obtain a borate dispersion of antibody-carrier magnetic beads; 1.4) adding a bovine serum albumin solution with a mass concentration of 1% to 5% to the borate dispersion of the antibody-carrier magnetic beads, reacting at room temperature for 1 to 4 hours to obtain a borate dispersion of the immunomagnetic beads; separating the immunomagnetic beads from the borate dispersion of the immunomagnetic beads by magnetic separation, washing the immunomagnetic beads with a phosphate buffer, and dispersing the washed immunomagnetic beads in a phosphate buffer to obtain an immunomagnetic bead dispersion.

8. The method for rapid visualization detection of enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: According to the weight percentage, the step 2) comprises the following steps: 2.1) dissolving 2 parts of enrofloxacin, 1 part of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.25 parts of sodium salt of N-hydroxysuccinimide sulfonate in N,N-dimethylformamide, and reacting at room temperature to obtain solution A; dissolving 5 parts of bovine serum albumin in phosphate buffer to obtain solution B; adding solution A dropwise to solution B, stirring at room temperature for reaction, dialyzing and centrifuging, and then taking the supernatant to obtain an enrofloxacin-bovine serum albumin complex solution; 2.2) washing the pre-labeled magnetic beads with a MES buffer solution, dispersing the washed pre-labeled magnetic beads in an activation solution, and reacting them at room temperature to obtain an activated pre-labeled magnetic bead dispersion; 2.3) separating the activated pre-labeled magnetic beads from the activated pre-labeled magnetic bead dispersion by magnetic separation, washing the activated pre-labeled magnetic beads with a borate buffer, and dispersing the washed activated pre-labeled magnetic beads in a borate buffer to obtain a borate dispersion of the activated pre-labeled magnetic beads; 2.4) mixing the activated pre-labeled borate dispersion of magnetic beads with the enrofloxacin-bovine serum albumin complex solution, and reacting them at room temperature to obtain a borate dispersion of unblocked labeled magnetic beads; 2.5) adding a bovine serum albumin solution with a mass concentration of 1% to 5% to the borate dispersion of unblocked labeled magnetic beads, reacting at room temperature to obtain a borate dispersion of labeled magnetic beads; separating the labeled magnetic beads from the borate dispersion of the labeled magnetic beads by magnetic separation, washing the labeled magnetic beads with a phosphate buffer, and after washing for times, dispersing the washed labeled magnetic beads in a phosphate buffer to obtain a labeled magnetic bead dispersion.

9. The method for rapid visualization detection of enrofloxacin based on the dual functions of magnetic separation and signal output of magnetic beads according to claim 1, characterized in that: The process of establishing the pre-drawn standard curve is as follows: according to step 3) to step 4), enrofloxacin standard solutions of different concentrations are treated respectively to obtain the detection value corresponding to each enrofloxacin standard solution, and the concentration of the enrofloxacin standard solution and the corresponding detection value are linearly fitted to obtain the standard curve.

10. An enrofloxacin visualization rapid detection kit for use in the visualization rapid detection method for enrofloxacin as claimed in any one of claims 1 to 9, characterized in that: The kit comprises an immunomagnetic bead dispersion and a labeled magnetic bead dispersion; in the immunomagnetic bead dispersion, the immunomagnetic beads are mainly formed by sealing carrier magnetic beads after surface modification with enrofloxacin monoclonal antibodies; the labeled magnetic bead dispersion is mainly formed by sealing pre-labeled magnetic beads after coupling with enrofloxacin-bovine serum albumin complexes; the carrier magnetic beads are carboxylated magnetic beads with a particle size of 100 to 1000 nm; and the labeled magnetic beads are carboxylated magnetic beads with a particle size of 100 to 1000 nm.

Citation Information

Patent Citations

  • Relaxation time immunosensing analysis method based on magnetic separation

    CN104614513A

  • Method for quickly detecting enrofloxacin in meat chicken by nanometer biosensor based on immunomagnetic beads and fluorescent quantum dots

    CN109283347A

  • Pseudomonas aeruginosa detection method based on low-field nuclear magnetic resonance imaging

    CN111351812A

  • Apparatus and method for b / f separation in immunoassay

    JP2006218442A

  • Method of analyzing biomaterials using a magnetic bead

    US20130122485A1

Cited By

  • Rapid detection method for enrofloxacin based on fluorescent covalent organic framework magnetic beads

    CN121656558A

  • A rapid detection method of enrofloxacin based on fluorescent covalent organic framework magnetic beads

    CN121656558B